These Q&A aim at clarifying regulatory requirements to obtain a marketing authorization for medicinal products in the EU (Q1) and at explaining the work of Committee on Herbal Medicinal Products (HMPC) regarding EU herbal monographs (Q2, Q3), as stakeholders involved in the manufacturing of Cannabis-derived substances may not have extensive experience with the EU pharmaceutical regulatory system.
Read the pdf